Following central nervous system insults, control of intracranial pressure may lessen the incidence of morbidity and mortality. Therapies to control intracranial pressure include osmolar agents, prevention of and control of seizures, drainage of cerebrospinal fluid, hypothermia, and barbiturates. Control of agitation and excessive patient movement are additional components in the management of ICP. Although opioids and benzodiazepines are generally effective, in a small subset of patients, alternative agents may be necessary. The authors present 2 children with increased ICP in whom propofol was used to provide sedation and control ICP. The use of propofol in this setting and its possible applications in the children with increased ICP are discussed.

Keywords:
Propofol, Intracranial pressure, Traumatic brain injury
1.
Becker DP, Miller JD, Ward JD, Greenberg RP, Young HF, Sakalas R: The outcome of severe head injury with early diagnosis and intensive management. J Neurosurg 1977;47:491–502.
2.
Thakker JC, Splaingard M, Zhu J, Babel K, Bresnahan J, Havens PL: Survival and functional outcome of children requiring endotracheal intubation during therapy for severe traumatic brain injury. Crit Care Med 1997;25:1396–1401.
3.
Sebel PS, Lowdon JD: Propofol: A new intravenous anesthetic. Anesthesiology 1989:260–277.
4.
Harris CE, Grounds RM, Murray AM, Lumley J, Royston D, Morgan M: Propofol for long-term sedation in the intensive care unit: A comparison with papaveretum and midazolam. Anaesthesia 1990;45:366–372.
5.
Beller JP, Pottecher T, Lugnier A, Mangin P, Otteni JC: Prolonged sedation with propofol in ICU patients: Recovery and blood concentration changes during periodic interruption in infusion. Br J Anaesth 1988;61:583–588.
6.
Sanchez-Izquierdo-Riera JA, Caballero-Cubedo RE, Perez-Vela JL, Ambros-Checa A, Cantalapiedra-Santiago JA, Alted-Lopez E: Propofol versus midazolam: Safety and efficacy for sedating the severe trauma patient. Anesth Analg 1998;86:1219–1224.
7.
Hemelrijck JV, Fitch W, Mattheussen M, Van Aken H, Plets C, Lauwers T: Effect of propofol on cerebral circulation and autoregulation in the baboon. Anesth Analg 1990;71:49–54.
8.
Nimkoff L, Quinn C, Silver P, Sagy M: The effects of intravenous anesthetic agents on intracranial pressure and cerebral perfusion pressure in two define models of brain edema. J Crit Care 1997;12:132–136.
9.
Watts ADJ, Eliasziw M, Gelb AW: Propofol and hyperventilation for the treatment of increased intracranial pressure in rabbits. Anesth Analg 1998;87:564–568.
10.
Herregods L, Verbeke J, Rolly G, Colardyn F: Effect of propofol on elevated intracranial pressure: Preliminary results. Anaesthesia 1988;43(suppl):107–109.
11.
Pinaud M, Lelausque J, Chetanneau A, Fauchoux N, Menegalli D, Souron R: Effects of propofol on cerebral hemodynamics and metabolism in patients with brain trauma. Anesthesiology 1990;73:404–409.
12.
Mangez JF, Menguy E, Roux P: Sedation par propofol à debit constant chez le traumatisé cranièn: Resultas préliminaires. Ann Fr Anesth Réanim 1987;6:336–337.
13.
Ravussin P, Guinard JP, Ralley F, Thorin D: Effect of propofol on cerebrospinal fluid pressure and cerebral perfusion pressure in patients undergoing craniotomy. Anaesthesia 1988;43(suppl):107–109.
14.
Farling PA, Johnston JR, Coppel DL: Propofol infusion for sedation of patients with head injury in intensive care. Anaesthesia 1989;44:222–226.
15.
Bullock R, Stewart L, Rafferty C, Teasdale GM: Continuous monitoring of jugular bulb oxygen saturation and the effects of drugs acting on cerebral metabolism. Acta Neurochir 1993;59(suppl):113–118.
16.
Stewart L, Bullock C, Rafferty C, Fitch W, Teasdale GM: Propofol sedation in severe head injury fails to control high ICP but reduces brain metabolism. Acta Neurochir 1994;60(suppl):544–546.
17.
Mergaert C, Herregods L, Rolly G, Collardyn F: The effect of 24 hour propofol or fentanyl sedation on intracranial pressure. Eur J Anesthesiol 1991;8:324–325.
18.
Sladen RN: Neuromuscular blocking agents in the intensive care unit: A two-edged sword. Crit Care Med 1995;23:423–428.
19.
Marion DW: Therapeutic moderate hypothermia for severe traumatic brain injury. J Intens Care Med 1997;12:239–248.
20.
Brussel T, Theissen JL, Vigfusson G, Lunkenheimer PP, Van Aken H, Lawin P: Hemodynamic and cardiodynamic effects of propofol and etomidate: Negative inotropic properties of propofol. Anesth Analg 1989;69:35–40.
21.
Egan TD, Brock-Utne JG: Asystole and anesthesia induction with a fentanyl, propofol, and succinylcholine sequence. Anesth Analg 1991;73:818–820.
22.
Hertzog JH, Campbell JK, Dalton HJ, Hauser GJ: Propofol anesthesia for invasive procedures in ambulatory and hospitalized children: Experience in the Pediatric Intensive Care Unit. Pediatrics 1999;103:e30.
23.
Trotter C, Serpell MG: Neurological sequelae in children after prolonged propofol infusions. Anaesthesia 1992;47:340–342.
24.
Saunders PRI, Harris MNE: Opisthotonic posturing and other unusual neurological sequelae after outpatient anesthesia. Anaesthesia 1992;47:552–557.
25.
Finley GA, MacManus B, Sampson SE, Fernandez CV, Retallick I: Delayed seizures following sedation with propofol. Can J Anaesth 1993;40:863–865.
26.
Lowenstein DH, Alldredge BK: Status epilepticus. N Engl J Med 1998;338:970–976.
27.
Parke TJ, Stevens JE, Rice ASC, Greenaway CL, Bray RJ, Smith PJ, Waldmann L: Metabolic acidosis and fatal myocardial failure after propofol infusion in children: Five case reports. Br Med J 1992;305:613–616.
28.
Strickland RA, Murray MJ: Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: Is there a relationship? Crit Care Med 1995;23:405–409.
29.
Bray RJ: Propofol infusion syndrome in children. Paediatric Anaesthesia 1998;8:491–499.
30.
Hanna JP, Ramundo ML: Rhabdomyolysis and hypoxia associated with prolonged propofol infusion. Neurology 1998;50:301–303.
31.
Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Gueant JL: Life-threatening anaphylactoid reactions to propofol. Anesthesiology 1992;77:275–280.
32.
Sosis MB, Braverman B: Growth of Staphylococcus aureus in four intravenous anesthetics. Anesth Analg 1993;77:766–768.
33.
Postsurgical infections associated with extrinsically contaminated intravenous anesthetic agent – California, Illinois, Maine, and Michigan, 1990. MMWR 1990;39:426–427.
34.
Gottardis M, Khunl-Brady KS, Koller W, Sigl G, Hackl JM: Effect of prolonged sedation with propofol on serum triglyceride and cholesterol concentrations. Br J Anaesth 1989;62:393–396.
35.
Valente JF, Anderson GL, Branson RD, Johnson DJ, Davis K Jr, Porembka DT: Disadvantages of prolonged propofol sedation in the critical care unit. Crit Care Med 1994;22:710–712.
36.
Matta BF, Lam AM, Strebel S, Mayberg TS: Cerebral pressure autoregulation and carbon dioxide reactivity during propofol-induced EEG suppression. Br J Anaesth 1995;74:159–163.
37.
Yamaguchi S, Midorikawa Y, Okuda Y, Kitajima T: Propofol prevents delayed neuronal death following transient forebrain ischemia in gerbils. Can J Anaesth 1999;46:593–598.
38.
Tobias JD: Tolerance, withdrawal, and physical dependency following long-term sedation and analgesia of children in the Pediatric ICU. Crit Care Med, in press.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.